NCT00561639已完成不适用
Benefit of Septifast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis
University Hospital, Grenoble1 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2007年12月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 76
- 试验地点
- 1
研究概览
简要总结
A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis. However, the clinical impact of being able to detect the DNA of these various agents is unknown. We propose to assess the benefit to patient care of the SeptiFast multiples PCR by answering three questions : 1/in patients with septic immunosuppression, does this kit evidence etiologic agents not revealed by classical methods? 2/Does the use of PCR results permit different diagnostic hypotheses to be considered? 3/Does having the SeptiFast results entail changes to the therapeutic plan?
详细描述
This study has double purpose :
- To compare the results obtained from the SeptiFast system with the results from classical microbiological sampling, in particular hemoculture, for immunosuppressed patients presenting sepsis.
- To perform a blind assessment of the benefit of septiFast care of these patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with onco-hematologic or cancerous pathology, or hematologic disease with chemotherapy and/or radiotherapy and/or some other immunosuppressant treatment in progress presenting an infection requiring hospitalisation and meeting the following criteria:
- •Sepsis (at least one of the following signs):
- •Fever > 38.2°C or hypothermia < 36°C
- •FO120 min
- •PA<120 mmHg (or 50 mmHg reduction in base numbers)
- •Respiratory F > 30/min
- •Confusion
- •Hyperleucocytosis (>12 G/l) or leucopenia (<4 G/l)
- •C-Reactive protein > 40
- •With or without organ dysfunction as defined by :
- •Hypoxia (PaO2/FiO2<300mmHg)
- •Oliguria (urine deficiency<0.5 ml/kg/h in probed patient)
- •Creatinine > 200umol/l
- •INR>1.5 or TCA>2 X control in the absence of anticoagulant treatment
- •Platelets < 100 G/l
- •Bilirubin > 35 umol/l
- •Lactatemia > 2 mmol/l
- •Arterial hypotension (PAS<90mmHg, or PAM<70mmHg or reduction of more than 40 mmHG if known hypertension)
排除标准
- •Minor patient
- •Pregnancy
- •A patient cannot be included again within 15 days of his/her preceding inclusion
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical Impact of the FilmArray Blood Culture Identification Panel Performed on Positive Blood Cultures From Intensive Care Patients With SepticemiaSepticemiaNCT03943719Cliniques universitaires Saint-Luc- Université Catholique de Louvain139
招募中
不适用
ew multiplex PCR strip for comprehensive diagnosis of infectious eye disease : multicenter prospective studyInfectious eye diseaseJPRN-UMIN000019201Tokyo Med and Dent University, RIKEN(Kobe Eye Center), Oita University3,000
已完成
不适用
Multiplex PCR for Severe Respiratory Infections During the COVID-19 PandemicViral PneumoniaNCT06349707Central Hospital, Nancy, France18
招募中
不适用
To Establish a Molecular Typing System for Early Diagnosis of Lung CancerLung CancerNCT05432128Singlera Genomics Inc.600
Unknown
不适用
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGSNon-small Cell Lung Cancer Stage INCT03172156Sun Yat-sen University100